These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 16416009)

  • 1. The significance of soluble CD138 in diagnosis of monoclonal gammopathies.
    Maisnar V; Tousková M; Tichý M; Krejsek J; Chrobák L; Voglová J; Malý J
    Neoplasma; 2006; 53(1):26-9. PubMed ID: 16416009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Soluble syndecan-1 levels in different plasma cell dyscrasias].
    Jánosi J; Sebestyén A; Mikala G; Petö M; Jákó J; Domján G; Németh J; Kis Z; Kopper L; Vályi-Nagy I
    Orv Hetil; 2005 Jan; 146(4):165-8. PubMed ID: 15751511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Importance of selected laboratory indicators in the differential diagnosis and monitoring of multiple myeloma].
    Maisnar V; Tousková M; Malý J; Krejsek J; Kmonícek M; Kopecký O
    Vnitr Lek; 2002 Apr; 48(4):290-7. PubMed ID: 12061177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble syndecan-1 levels in different plasma cell dyscrasias and in different stages of multiple myeloma.
    Jánosi J; Sebestyén A; Mikala G; Németh J; Kiss Z; Vályi-Nagy I
    Haematologica; 2004 Mar; 89(3):370-1. PubMed ID: 15020284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma].
    Scudla V; Budíková M; Pika T; Minarík J; Zemanová M; Bacovský J; Heincová V;
    Vnitr Lek; 2006 Mar; 52(3):232-40. PubMed ID: 16722154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival.
    Lovell R; Dunn JA; Begum G; Barth NJ; Plant T; Moss PA; Drayson MT; Pratt G;
    Br J Haematol; 2005 Aug; 130(4):542-8. PubMed ID: 16098068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
    Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA
    Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum syndecan-1 in patients with newly diagnosed monoclonal proteinemia.
    Schaar CG; Vermeer HJ; Wijermans PW; Huisman W; le Cessie S; Kluin-Nelemans HC
    Haematologica; 2005 Oct; 90(10):1437-8. PubMed ID: 16219583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY;
    Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma].
    Scudla V; Budíková M; Petrová P; Minarík J; Pika T; Bacovský J; Adamová D; Langová K;
    Klin Onkol; 2010; 23(3):171-81. PubMed ID: 20608327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The comparison of serum levels of selected biomarkers in monoclonal gammopathy of undetermined significance and multiple myeloma].
    Scudla V; Budíková M; Pika T; Bacovský J; Minarík J; Heinzová V; Langová K
    Cas Lek Cesk; 2009; 148(7):315-22. PubMed ID: 19642297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAS mutations are uncommon in multiple myeloma and other monoclonal gammopathies.
    Martín P; Santón A; García-Cosío M; Bellas C
    Int J Oncol; 2005 Oct; 27(4):1023-8. PubMed ID: 16142319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma.
    Woitge HW; Pecherstorfer M; Horn E; Keck AV; Diel IJ; Bayer P; Ludwig H; Ziegler R; Seibel MJ
    Br J Cancer; 2001 Feb; 84(3):344-51. PubMed ID: 11161399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating sCD138 and some angiogenesis-involved cytokines help to anticipate the disease progression of early-stage B-cell chronic lymphocytic leukemia.
    Wołowiec D; Dybko J; Wróbel T; Urbaniak-Kujda D; Jaźwiec B; Tomaszewska-Toporska B; Kapelko-Słowik K; Potoczek S; Kuliczkowski K
    Mediators Inflamm; 2006; 2006(3):42394. PubMed ID: 16951490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Monitoring markers of bone turnover in multiple myeloma].
    Spicka I; Spacek P; Hulejová H; Procházka B; Cieslar P; Chrz M; Válková V; Klener P
    Vnitr Lek; 1999 Aug; 45(8):463-7. PubMed ID: 11045145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
    Martín P; Santón A; Bellas C
    Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High serum interleukin-2 levels in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma.
    Cimino G; Avvisati G; Amadori S; Di Gregorio AO; Magliocca V; Petrucci MT; Sgadari C
    Nouv Rev Fr Hematol (1978); 1989; 31(5):329-32. PubMed ID: 2587201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma.
    Scudla V; Ordeltova M; Bacovsky J; Vytrasova M; Sumna E; Martinek A; Horak P
    Neoplasma; 2003; 50(5):363-71. PubMed ID: 14628090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Syndecan-1 in multiple myeloma: relationship to conventional prognostic factors.
    Aref S; Goda T; El-Sherbiny M
    Hematology; 2003 Aug; 8(4):221-8. PubMed ID: 12911939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and different stages of multiple myeloma.
    Scudla V; Petrova P; Minarik J; Pika T; Bacovsky J
    Neoplasma; 2011; 58(6):499-506. PubMed ID: 21895403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.